Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Enewold, Lindsey ^a   Thomas, Anish ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; NON SMALL CELL LUNG CANCER; PRIVATE HEALTH INSURANCE; SENSITIVITY AND SPECIFICITY; SMOKING; UNITED STATES; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PRACTICE; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR DIAGNOSIS; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; ERLOTINIB HYDROCHLORIDE; FEMALE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PRACTICE PATTERNS, PHYSICIANS'; RECEPTOR, EPIDERMAL GROWTH FACTOR; UNITED STATES;

EID: 84976444764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156728     Document Type: Article

References (34)

1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society, 2015.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98 PMID: 11784875
3. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 2010; 10:760-774. doi: 10.1038/nrc2947 PMID: 20966921
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311. PMID: 15329413
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. PMID: 15118073
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. PMID: 15118125
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957. doi: 10.1056/NEJMoa0810699 PMID: 19692680
8. Zhou CC, Wu YL, Chen GY, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 2011; 12:735-742. doi: 10.1016/S1470-2045(11)70184-X PMID: 21783417
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology 2012; 13:239-246. doi: 10.1016/S1470-2045(11)70393-X PMID: 22285168
10. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for firstline treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncology 2014; 15:213-222. doi: 10. 1016/S1470-2045(13)70604-1 PMID: 24439929
11. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29:2121-2127. doi: 10.1200/JCO.2010.31.8923 PMID: 21482992
12. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8:1343-1343.
13. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012; 10:1236-1271. PMID: 23054877
14. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32:3673-3679. doi: 10.1200/JCO.2014.57.3055 PMID: 25311215
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer, version 5.2015 2015.
16. Ellis PM, Verma S, Sehdev S, Younus J, Leighl NB. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol 2013; 8:1136-1141. doi: 10.1097/JTO.0b013e31829f6a43 PMID: 23887170
17. Sequist LV, Joshi VA, Janne PA, Muzikansky A, Fidias P, Meyerson M, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007; 12:90-98. PMID: 17285735
18. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. J Clin Oncol 2009; 27:1394-1400. doi: 10.1200/JCO.2008.18. 7658 PMID: 19224850
19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. PMID: 15118073
20. Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res 2009; 9:131. doi: 10.1186/1472-6963-9-131 PMID: 19643018
21. Moreira AL, Thornton RH. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer 2012; 13:334-339. doi: 10.1016/j.cllc.2012.01.004 PMID: 22424871
22. Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005; 23:9079-9088. PMID: 16301598
23. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014; 12:1738-1761. PMID: 25505215
24. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350-2357. doi: 10.1200/JCO.2007.15.2280 PMID: 18467727
25. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166-2171. PMID: 16609030
26. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2005; 11:2106-2110. PMID: 15788655
27. Zhang W, McQuitty EB, Olsen R, Fan H, Hendrickson H, Tio FO, et al. EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma. Arch Pathol Lab Med 2014; 138:543-545. doi: 10.5858/arpa.2013-0311-OA PMID: 23937608
28. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011; 6:28-31. doi: 10.1097/JTO.0b013e3181fb4fe2 PMID: 21107288
29. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012; 18:6169-6177. doi: 10.1158/1078-0432. CCR-11-3265 PMID: 23014527
30. Araujo LH, Timmers C, Bell EH, Shilo K, Lammers PE, Zhao W, et al. Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing. J Clin Oncol 2015; 33:1966-73. doi: 10.1200/JCO.2014.59.2444 PMID: 25918285
31. McQuitty E, Zhang W, Hendrickson H, Tio FO, Jagirdar J, Olsen R, et al. Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. Arch Pathol Lab Med 2014; 138:390-394. doi: 10.5858/arpa.2013-0225-OA PMID: 23802852
32. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909. PMID: 16043828
33. Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006; 118:180-184. PMID: 16003726
34. Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. Lung Cancer 2013; 82:469-476. PMID: 24396885